%0 Journal Article
%T Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches.
%A Vathiotis IA
%A Johnson JM
%A Luginbuhl A
%A Cognetti D
%A Curry J
%A Argiris A
%A Vathiotis IA
%A Johnson JM
%A Luginbuhl A
%A Cognetti D
%A Curry J
%A Argiris A
%A Vathiotis IA
%A Johnson JM
%A Luginbuhl A
%A Cognetti D
%A Curry J
%A Argiris A
%J Cancer Treat Rev
%V 109
%N 0
%D Sep 2022
%M 35868194
%F 13.608
%R 10.1016/j.ctrv.2022.102437
%X Immunotherapy and in particular programmed cell death protein 1 (PD-1) inhibitors have been applied not only in the management of recurrent or metastatic disease but also as component of potentially curative treatment for many solid tumors. The incorporation of immunotherapy as neoadjuvant and /or adjuvant therapy in the treatment paradigm of locally advanced squamous cell carcinoma of the head and neck (SCCHN) is appealing with the goals of enhancing antitumor efficacy and, at the same time, reduce toxicity. This review analyzes the rationale for employing immunotherapy in the neoadjuvant and adjuvant settings, reviews the results of relevant clinical trials, and examines the potential benefits and caveats of neoadjuvant and/or adjuvant approaches in patients with SCCHN.